SEARCH WITHIN CONTENT
VOLUME 1 , ISSUE 4 ( October-December, 2017 ) > List of Articles
Milind Suryavanshi, Hari ML Meena, G Babu, Uday RS Namburi, Varanasi Subhose, Bhagwan S Sharma
Keywords : St. George Respiratory Questionnaire, Stable chronic bronchitis, Vasavaleha,Kasa roga
Citation Information : Suryavanshi M, Meena HM, Babu G, Namburi UR, Subhose V, Sharma B S. Clinical Efficacy and Safety of “Vasavaleha” in the Management of Stable Chronic Bronchitis: A Prospective Open Label Multicenter Study. J Res Ayurvedic Sci 2017; 1 (4):231-237.
License: CC BY-NC 3.0
Published Online: 00-12-2017
Copyright Statement: Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.
Introduction: Chronic bronchitis is one of the common clinical problems seen in middle–older age group and occurs as a result of inflammation and swelling of the lining of the airways, leading to narrowing and obstruction generally resulting in persistent cough, associated with wheezing, chest pain, and shortness of breath. Chronic bronchitis can be symptomatically compared with Kasa Roga in Ayurveda. Aims and objectives: To evaluate the efficacy and safety of Vasavaleha in patients suffering from stable chronic bronchitis (CB). Materials and methods: A prospective, open label multicenter study was carried out at three peripheral units under intramural clinical research program from 2012 to 2013. One hundred and twenty six patients satisfying the selection criteria were enrolled at the Outpatient Department of the centers and were administered Vasavaleha (10 gm) twice daily after food with water for 12 weeks. Follow-up was done finally after 2 weeks without medication. Laboratory parameters were assessed at baseline, 42nd day, and at the end of the treatment period of 12 weeks (i.e., 84th day). Paired sample t-test was used to compare mean change from baseline to the 84th day. A p-value of <0.05 was considered significant. Results: At the end of 12 weeks, statistically significant improvement was observed in clinical symptoms of CB and also in peak expiratory flow rates (PEFR), forced expiratory volume (FEV1), and St. George Respiratory Questionnaire (SRGQ) Score (p < 0.001). The treatment was found to be safe and effective in the patients of CB as all the safety parameters were within the normal range. No adverse drug reaction or adverse event was reported during the trial period. Conclusion: Vasavaleha in the above prescribed dose is found to be effective and safe in the management of stable CB.